<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
  <channel>
    <title>oncbrain — oncology meeting digest</title>
    <link>https://oncbrain.oncologytoolkit.com/</link>
    <description>AI-summarized oncology meeting studies, curated by a subspecialist. One item per study.</description>
    <language>en</language>
    <lastBuildDate>Tue, 02 Jun 2026 00:00:00 GMT</lastBuildDate>
    <item>
      <title>Breast RT + Systemic Therapy Concurrency Review (Speers)</title>
      <link>https://oncbrain.oncologytoolkit.com/2026-06-02/#breast-rt-systemic-concurrent</link>
      <guid isPermaLink="true">https://oncbrain.oncologytoolkit.com/2026-06-02/#breast-rt-systemic-concurrent</guid>
      <pubDate>Tue, 02 Jun 2026 00:00:00 GMT</pubDate>
      <category>breast</category>
      <description>[Confirmatory] T-DXd ILD 9.6% vs T-DM1 1.6% (DESTINY-Breast05); ASCO26 PK-guided concurrency framework for breast RT + systemic agents.</description>
    </item>
    <item>
      <title>EORTC Cutaneous Lymphoma RT Recommendations</title>
      <link>https://oncbrain.oncologytoolkit.com/2026-05-22/#eortc-cutaneous-lymphoma-rt</link>
      <guid isPermaLink="true">https://oncbrain.oncologytoolkit.com/2026-05-22/#eortc-cutaneous-lymphoma-rt</guid>
      <pubDate>Fri, 22 May 2026 00:00:00 GMT</pubDate>
      <category>lymphoma</category>
      <description>[Confirmatory] EORTC expert consensus formalizes low-dose RT recommendations across all primary cutaneous lymphoma entities; no RCT dose-comparison data exist.</description>
    </item>
  </channel>
</rss>